Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma

Abstract

Studies on the association between the Ile to Val polymorphism at codon 655 of the human epithelial growth factor receptor 2 (HER-2) gene and susceptibility to breast cancer have been reported for almost all ethnic populations, with both positive or negative conclusions. No study, however, has yet been focused on the possible association between this gene and its predisposition to benign breast lesions, especially on risk for fibroadenoma. We aimed to study the association of the single nucleotide polymorphism V655 HER-2 gene polymorphism with histologically verified breast fibroadenoma risk. We conducted a molecular epidemiological case-control study of 70 breast fibroadenoma cases without cellular atypia and 172 healthy female controls. We found that the Val variant allele and genotype frequency of this polymorphism is higher in cases with fibroadenoma; however, this difference was not significant (allele Val 655: 27.86 and 22.67% in fibroadenoma and controls, respectively; genotype Ile/Val: 35.71 and 38.37% and Val/Val: 10.0 and 3.49% in fibroadenoma and controls, respectively). Applying logistic regression analysis, we found an increased risk of fibroadenoma formation in carriers of the Val allele (odds ratio = 1.17; 95% confidence interval = 0.67-2.05), in which the highest risk was associated with homozygous genotype (odds ratio = 3.07; 95% confidence interval = 0.97-9.72), but this risk was not significant. Stratification by age (cut-off 45 years) revealed the highest risk of fibroadenoma among young women homozygous for the Val allele (odds ratio = 3.30). The risk, however, was slightly increased (odds ratio = 1.24) among older carriers of the aberrant allele in their genotype as well, but it was not significant. In spite of insignificant differences, our results indicate that HER-2 Ile655Val polymorphism, especially in a homozygous form might play some role in the etiology of breast fibroadenoma formation. The significance of this susceptibility, however, will have to be verified by larger studies.

Development of high throughput microfluidic cell culture chip for perfusion 3-dimensional cell culture-based chemosensitivity assay

“…The responses of cancer cells to anti-cancer drugs show high degree of variation [2]. It is becoming clear that each individual patient's tumor is genotypically and phenotypically different [3,4]. For a more effective and personalized chemotherapy, an in vitro chemosensitivity assay is necessary to evaluate which anti-cancer drugs and their conditions the patient's cancer cells will respond to.…”

Malignant tumors of the uterine corpus: molecular background of their origin

“…An approach, very popular in the recent past, but still quite used, is observing the aberrant gene expression, mostly in order to find some markers that could be used as a significant sign of certain tumorigenesis of an actual tumor type. This approach is closely connected with epigenetic analyses because a different gene expression can (in many cases) be regulated by epigenetic factors that involve histone modifications: hypomethylation or hypermethylation, deacetylation, or polycomb-group proteins [2][3][4]. Most frequently, the degree of methylation of tumor suppressor genes is monitored, specifically in their upstream region of promoters with higher concentration of CpG sites which can have a critical effect on the gene expression.…”

In vitro assays for the evaluation of drug resistance in tumor cells

“…These drugs have a few structural and functional similarities except that they are large, hydrophobic molecules and may enter the cell by passive diffusion across the cell membrane lipid bilayer [2]. In addition, it is becoming clear that each individual patient's tumor is genotypically and phenotypically different [3,4]. For these reasons, numerous attempts have been made to develop in vitro or in vivo assays that might predict individual response or resistance [5][6][7][8].…”